Stocks
Eiger BioPharmaceuticals IncEIGR
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing therapies for rare and infectious diseases, with a focus on hepatitis delta virus (HDV). Its lead candidate, lonafarnib, has received FDA approval for Hutchinson-Gilford progeria syndrome, and the company is advancing a pipeline targeting unmet medical needs. Investors track Eiger for its HDV program and regulatory milestones.
Congressional Interest in Eiger BioPharmaceuticals Inc (EIGR)
1 member of Congress has disclosed 1 trade in Eiger BioPharmaceuticals Inc (EIGR), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading EIGR?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-10-07 | MICHAEL T. MCCAUL | sell | $1K-$15K |